Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Cephalon Stories

2014-04-03 12:30:25

LONDON, April 3, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Parkinson's Disease Therapeutics Market to 2019 - Pipeline Shows Shift Towards Long Term Disease Management Parkinson's Disease Therapeutics Market to 2019 - Pipeline Shows Shift Towards Long Term Disease Management SummaryGBI Research has released the pharma report "Parkinson's Disease Therapeutics Market to 2019 - Pipeline Shows Shift Towards Long Term Disease Management". The...

2014-02-04 20:22:43

DUBLIN, February 5, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/f3g6bf/pain_management) has announced the addition of the "Concise Analysis on the International Pain Management Treatment Markets" [http://www.researchandmarkets.com/research/f3g6bf/pain_management ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Pain management describes a particular set of drugs, analgesics, which...

2014-02-04 08:34:45

DUBLIN, Feb. 4, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Bendamustine Hydrochloride for Injection, 25 mg/vial and 100 mg/vial. Actavis' ANDA product is a generic version of Cephalon's Treanda(®), a treatment for chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Cephalon, Inc. filed suit against Actavis on January 31,...

2014-01-27 08:28:11

SUNNYVALE, Calif., Jan. 27, 2014 /PRNewswire/ -- Sorbent Therapeutics, Inc., a biopharmaceutical company developing therapies for cardiovascular and renal diseases, today announced that Tom O'Neil has joined the company as Chief Financial Officer. Mr. O'Neil brings more than 15 years of industry experience to Sorbent. In this role, he will oversee Sorbent's financial operations, reporting directly to Detlef Albrecht, M.D., Sorbent's President and Chief Executive Officer. "Tom...

2014-01-22 12:27:21

LONDON, Jan. 22, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market TransformationSummaryGBI Research has released its pharmaceuticals report, "Alzheimer's Disease Therapeutics Market to...

2014-01-09 08:28:57

SAN DIEGO, Jan. 9, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced the addition of industry veteran William Marth, as Chairman of the Board of Directors. Mr. Marth was the President and CEO of Teva - Americas until the end of 2012, and served as a senior advisor to Teva Pharmaceuticals until the end of 2013. During his tenure at Teva -...

2013-12-02 04:20:51

SEATTLE, Dec. 2, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that it has received a $5 million milestone payment from Teva Pharmaceutical Industries Ltd. (Teva) related to the achievement of a sales milestone for TRISENOX(®) (arsenic trioxide). TRISENOX was acquired from CTI by Cephalon, Inc. (Cephalon). Cephalon was subsequently acquired by Teva. The milestone was paid pursuant to an acquisition agreement for TRISENOX entered into...

2013-11-13 08:28:56

Trisenox(®) is now available in Canada MONTREAL, Nov. 13, 2013 /CNW/ - Health Canada has recently approved Trisenox® (arsenic trioxide) for relapsed or refractory acute promyelocytic leukemia (APL). This was made possible by a decision from Health Canada's Therapeutic Products Directorate to remove a prior regulatory prohibition on arsenic containing drug therapies for use in humans and by granting priority review. Trisenox® has been available since 2000 for the treatment...

2013-09-09 08:26:28

Thomas E. D'Ambra, Ph.D. to Retire as President and CEO; to be Named Chairman of the Board ALBANY, N.Y., Sept. 9, 2013 /PRNewswire/ -- Albany Molecular Research, Inc. (NASDAQ: AMRI), a leading global contract research and manufacturing organization, announced that Thomas E. D'Ambra, Ph.D. will retire as President and Chief Executive Officer of the Company, effective December 31, 2013. Dr. D'Ambra will be named the Company's non-executive Chairman of the Board of Directors on the...

2013-08-19 12:24:59

Company names J. Kevin Buchi President and Chief Executive Officer, Pete A. Meyers Chief Financial Officer, and Lesley Russell, MBChB, MRCP Chief Operating Officer MALVERN, Pa., Aug. 19, 2013 /PRNewswire/ -- TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule SMAC mimetic drugs to treat cancer, today announced the appointment of a new senior executive leadership team with the goal of accelerating the development of the company and its lead product...